University of Arkansas, Fayetteville

ScholarWorks@UARK
Biological Sciences Undergraduate Honors
Theses

Biological Sciences

5-2020

The Effect of Protein and Omega-3 Fatty Acid Supplementation on
Regulation of Sleep and Mood in Postmenopausal Women
Caroline Baughn

Follow this and additional works at: https://scholarworks.uark.edu/biscuht
Part of the Human and Clinical Nutrition Commons

Citation
Baughn, C. (2020). The Effect of Protein and Omega-3 Fatty Acid Supplementation on Regulation of Sleep
and Mood in Postmenopausal Women. Biological Sciences Undergraduate Honors Theses Retrieved from
https://scholarworks.uark.edu/biscuht/41

This Thesis is brought to you for free and open access by the Biological Sciences at ScholarWorks@UARK. It has
been accepted for inclusion in Biological Sciences Undergraduate Honors Theses by an authorized administrator of
ScholarWorks@UARK. For more information, please contact scholar@uark.edu.

The Effect of Protein and Omega-3 Fatty Acid Supplementation on Regulation of Sleep and
Mood in Postmenopausal Women

An Honors Thesis submitted in partial fulfillment of the requirements for Honors Studies in
Biology

By

Caroline Baughn

Spring 2020
Biological Sciences
J. William Fulbright College of Arts and Sciences
The University of Arkansas

Acknowledgements
I would like to thank Dr. Jamie I. Baum for the opportunity to work in her lab and
take part in this research project. The research for this honors thesis would not have been
possible without her and her assistance. I have truly grown and learned much from her
during my time in the laboratory. I would also like to thank graduate student Aubree
Hawley for allowing me to work with her. I am truly grateful for her time and dedication,
as she taught me much during my time with her. Additionally, thank you to my
committee members: Dr. Jeremy Beaulieu, Dr. Daniel Lessner, and Dr. Matt Clay. Last,
but not least, thank you to my parents for their unconditional love and support. I would
not have ever dreamed of what I could accomplish without them.

2

Table of Contents
Acknowledgements………………………………………………………………………2
Introduction and Background………………………………………………………….4
Aging and associated ailments...……………...…………………………………...4
Objective and hypothesis………………………………………………………….6
Materials and Methods………………………………………………………………….7
Study recruitment and Participation..……………………………………………...7
Intervention……………….…….…...……………………………………………8
Educational Materials………….……………………………………………….…8
Anthropometrics…...……….……………………………………………………....9
Sleep Assessment………………………...…………………………………….......9
Mood Assessment……………………….…………………….………………….10
Statistical Analysis ……………………....……………………………………….11
Results…………………………………………………………………………………...11
Participant characteristics……………………………………..………………….11
Anthropometrics…………………………………………………………………13
Sleep………....…………………………………………………………………...16
Mood……….……………………………………………………………….……21
Discussion………………..……………….…………………………………….……….25
References……………………………………………………………………………….29
Appendices.……………………………………………………………………………...32
Appendix 1: IRB Approval Letter 2018…………………………………………32
Appendix 2: IRB Approval Letter 2019………………………………………....33

3

Introduction and Background
The older population of the United States is in a period of rapid growth [1]. The
population of those in the United States aged 65 or older will double to about 72 million
in the next 25 year [1]. This population is at increased risk for obesity, chronic diseases,
decreased quality of life, and premature death. Therefore, guidelines for healthy aging are
desperately needed. In 2015 alone, 67.7% of adults in the United States aged 65 or older
reported having two or more chronic conditions [2]. Treatment for those in the older
population afflicted by multiple chronic conditions alone accounts for 66% of the United
States’ total health care budget [1]. In 2018, for the third year in a row, Arkansas was one
of nine states with an adult obesity rate at or above 35 percent [3]. The obesity prevalence
in Arkansans 65 years of age and older was reported to be 30.1% for 2018 and is
projected to continue with an increasingly upward trajectory. In the United States,
Arkansas was identified as having the 4th highest-ranked state with regard to overweight
and obesity percentiles for adults. Arkansas was also identified as the 4th highest-ranked
state for number of adults diagnosed with type 2 diabetes mellitus (T2DM). Additionally,
in Arkansas alone 23.4% of adults aged 65 years of age or older were currently diagnosed
with T2DM in 2015, with an expected increase in this percentage [2]. Poor sleep has been
identified as one potential cause for this dramatic decline in health [4].
Sleep disorders are highly prevalent in older adults with 50% or more older adults
being currently diagnosed with a clinical sleeping disorder [5]. A lack of sleep schedule
regularity in addition to poor sleep quality puts older adults at significantly higher risk for
cognitive and functional decline [5]. Sleep loss in older adults has been specifically
linked to an increased risk of T2DM and obesity [4]. While aging is linked to a general
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decline in total sleep time and sleep efficiency, sleep efficiency has been shown to
significantly decrease past age 60 [6].
Adequate nutrition has the potential to combat dysregulated sleep and mood.
Preference for fat-based dietary patterns have also been linked to poor sleep quality [7].
Those with poor quality sleep have been shown to typically select their diet from a
smaller range of food groups, with low protein intake being cited as a common factor [7].
Omega-3 fatty acid (O3FA) supplementation has been shown to prevent cognitive
impairments, in both the long- and short-term, that arise from chronic sleep deprivation
[8]. Additionally, a shift in dietary intake away from O3FAs toward saturated fats in
Western countries, such as in the United States, has been linked to the rise in depression
and other neurological disorders [9]. In conjunction with this linkage, O3FAs have
demonstrated potential use in an antidepressant role [9].
Nutrition is a key factor in the prevention of muscle loss and body fat gain often
observed with age [10,11]. Diets high in O3FAs have been linked to healthy aging [10].
Increasing consumption of O3FAs has shown decreased risk of cardiovascular disease
and potential sleep quality improvement through a decrease in overall body fat. In
addition, high protein diets have also been linked to healthy aging through decreasing
body fat and increasing muscle mass [11]. Protein needs increase as individuals age, and
the impairments on physical function from a lack of protein is most obvious in older
adults [11]. The synergistic effects of protein and O3FA supplementation on sleep
quality, mood, and body composition are currently unknown.
For this study, measures to evaluate healthy aging will include weight, Body Mass
Index (BMI), waist circumference measurements, and waist-to-hip ratios. BMI and waist
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circumference measurements are both recognized as important measures of obesity and
weight-related health risks [12]. Health risks increase as BMI increases, but within the
obesity category (BMI ≥ 30) the National Institutes of Health (NIH) recognizes a graded
scale at each obese category based upon waist circumference [12]. A higher waist
circumference is associated with more health risks within a given BMI category.
Specifically, a waist circumference >102cm for men or >88cm for women is considered a
high waist circumference by the NIH [12]. Just as poor sleep is related to obesity and
other chronic illnesses, obesity appears to also contribute to shorter sleep duration in a
vicious cycle. Studies in adults have shown a significant decline in hours of sleep as BMI
rises [13].
The effects of aging are experienced greatly in a specific demographic—post
menopausal women [14,15,16,17]. Postmenopausal women have been found to present
larger waist circumferences and larger waist-to-hip ratios than premenopausal women in
studies [14]. Gain of abdominal fat during menopause for postmenopausal women has
also been shown to display statistical significance even after adjustment for age and total
body fat mass when compared to premenopausal women [15]. At the core of complaints
given among those who are postmenopausal is sleep disturbance [16]. Mood disturbance
among postmenopausal women is also exacerbated beyond that found with aging alone.
Women are twice as likely as men to be afflicted by depressive symptoms and disorders,
and this risk is heightened upon reaching the transition toward becoming postmenopausal
[17].
The objective of this project was to determine whether increasing protein and
O3FAs in the diet of aging postmenopausal women for 16 weeks would improve sleep
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and overall well-being. We hypothesized that increased consumption of both protein and
O3FAs would promote healthier aging in postmenopausal women through improved
quality of sleep, reduced body weight, improved body composition, and improved mood.
Signs of healthier aging would be shown through improved health measures—sleep
quality, weight, BMI, waist-to-hip ratios, and overall mood. The demographic selected
for this study was chosen as to negate the hormonal influence as well as to provide data
on a population with little available research.

Materials and Methods
Subject Recruitment and Participation
Prior to subject recruitment, the study was submitted to the University of
Arkansas’ Institutional Review Board for approval and was registered on
clinicaltrials.gov, clinical trial number: NCT0303041. Subjects were recruited on a
voluntary basis through advertisement in the University of Arkansas Newswire, social
media, and local businesses. In order to participate in the study, subjects were required to
be postmenopausal women with a last reported menstrual cycle of 12 months or more
prior, be absent of hormone replacement therapy (HRT), have no known food allergies,
regularly eat breakfast, consume fatty fish 4 times or less per month, not taking
medications that impact appetite, blood coagulation, metabolism, or blood lipids, not
consuming protein or O3FA related supplements, and have an initial Pittsburgh Sleep
Quality Index (PSQI) of 5 or greater, as this score indicated dysregulated sleep. All
subjects completed a brief screening and filled out a consent form prior to enrolling in the
study. Participants were recruited on a rolling basis and randomly assigned a treatment
group. A total of 34 women, ages 32 to 82, completed the 16-week study.
7

Intervention
A total of 40 participants were recruited to partake in this 16-week randomized,
single-blind, controlled study. Six participants dropped out of the study at various stages
for different reasons—study visits were time-consuming to attend in the morning or they
did not want to consume all necessary supplements. Thirty-four participants were
randomly assigned to a control group or one of four treatment groups: 1) control—no
supplements given, 2) 25 grams of whey protein, 3) 4.3 grams of omega-3 fatty acid
supplements, 4) 25 grams of whey protein and 4.3 grams of soybean oil placebo
supplements, or 5) 25 grams of whey protein and 4.3 grams of O3FAs supplements.
Protein was consumed prior to 10:00 am, and the O3FA or placebo supplements were
consumed in a 2.15 gram dose before 10:00 am as well as with the evening meal. Waistto-hip ratio measurements, height, weight, Pittsburgh Sleep Quality Index (PSQI)
questionnaire results, and Profile of Mood States questionnaire results were recorded at
the baseline, week 4, week 8, week 12, and week 16 visits. All five laboratory visits
required fasting the night before (10-12h), as the blood samples were drawn by a certified
phlebotomist to assess sleep and metabolic blood markers. In addition, sleep was assessed
at baseline, 8 weeks, and 16 weeks.
Educational Materials
Participants were given a booklet that corresponded to their randomly assigned
groups’ dietary intervention. All booklets included a standard study day schedule and
checklist, as well as instructions for the sleep ActiGraph sleep monitors and sleep diary.
Each booklet included a breakfast recipe section that was to be modified to incorporate
the protein powder for participant groups assigned to a whey protein containing group.
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Anthropometrics
Height, weight, and waist circumference, and hip circumference were measured at
the baseline, week 4, week 8, week 12, and week 16 visits. Body height was measured to
the nearest 0.01 cm using a stadiometer (Detecto, St. Louis, MO) while participants were
barefoot, in the free-standing position. Body weight of participants was measured in the
fasting state without shoes to the nearest 0.01 kg using calibrated balance scales (Detecto,
St. Louis, MO). Body mass index (BMI) was calculated as weight (kg) divided by height
(m) squared. Waist measurements were taken using the belly button as the standard
position of the waist for each participant using a soft tape measure, and rounding to the
nearest 0.1 cm. Hip measurements were taken at the widest point below the waist using
the aforementioned soft tap measure, and rounding to the nearest 0.1 cm. Waist-to-hip
ratios were recorded by dividing the waist measurement (cm) by the hip measurement
(cm).
Sleep Assessment
Sleep quality was determined via wrist actigraphy. Wrist actigraphy utilizing the
Cole-Kripke algorithm has been validated with high sensitivity, moderate specificity and
high accuracy when compared to polysomnography, the current gold standard [18]. Each
participant was required to wear an ActiGraph monitor on the non-dominant wrist for 7
days during the month of the intervention. Wrist actigraphy was utilized the 7 days prior
to the baseline, week 8, and week 16 visits. 60Hz was utilized as the sample rate, as this
rate has been verified for sleep quality analysis. In addition to wearing the ActiGraph
monitor, participants also filled out a 7-day sleep diary to accompany the data collection
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via wrist actigraphy. Sleep times were verified and corrected by comparing the sleep
diaries against the raw data downloaded.
The Pittsburgh Sleep Quality Index (PSQI) questionnaire was utilized to measure
subjective sleep quality. The PSQI questionnaire has high consistency and validity [19].
The PSQI questionnaire has also been specifically validated for use in older women of
multiple ethnic groups [20]. The PSQI questionnaire was administered during all five
visits—baseline, week 4, week 8, week 12, and week 16.
Mood
Mood was measured through administration of the commonly used Profile of
Mood States (POMS) questionnaire [21]. The POMS questionnaire has been specifically
validated and shown internal consistency in measuring mood in postmenopausal women
[21]. The POMS questionnaire was administered at baseline, week 4, week 8, week 12,
and week 16. Participants defined their mood on a 5-point Likert scale. The POMS
questionnaire provided a score for Total Mood Disturbance (TMD), Anger-Hostility
(Anger), Confusion-Bewilderment (Confusion), Depression-Dejection (Depression),
Fatigue-Inertia (Fatigue), Tension-Anxiety (Tension), and Vigor-Activity (Vigor). For
the Vigor measure a higher score, or a numerical increase in value after score comparison
over time signifies an improvement in mood. For Total Mood Disturbance (TMD),
Anger, Confusion, Depression, Fatigue, and Tension a lower score, or a numerical
decrease in value upon comparing scores over time signified an improvement in mood.
TMD was calculated using the following equation: TMD = (Tension-Anxiety) +
(Depression-Dejection) + (Anger-Hostility) + (Fatigue-Inertia) + (ConfusionBewilderment) – (Vigor-Activity).
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Statistical Analysis
One-way repeated measures analysis of variance (ANOVA) was used to assess
the differences in BMI, waist-to-hip ratio, Global PSQI Scores, wrist actigraphy, and
POMS scores between the five treatments over the course of the 16-week intervention.
One-way ANOVA was used to look at the total change from baseline compared to the
end of the 16-week intervention for Global PSQI scores and POMS TMD scores. Clinical
biomarker differences were determined using repeated-measures ANOVA. A p-value <
0.05 indicates statistical significance. Prism GraphPad Software Version 8.0 (La Jolla,
CA) was used for all analyses.

Results
Participant Characteristics
A total of 34 participants completed the study. Table 1 shows the baseline
characteristics of the participants in the study including: age, height, weight, body mass
index (BMI), waist-to-hip ratio, global PSQI score, and total mood disturbance POMS
score. All baseline characteristics are reported in Table 1 as the mean ± standard
deviation.
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Table 1. Participant Characteristics
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Anthropometrics: BMI, Waist Circumference, and Waist-to-Hip Ratio Measurements
The calculated BMI, waist circumference, and waist-to-hip ratio measurements
taken at each visit were compiled. The average of each per group was determined for
each of the listed measures, and the results were standardized as change from baseline.
The line graph in Figure 1A shows the average BMI for each of the five
treatment groups over the course of the study after controlling for baseline. A one-way
repeated measures ANOVA did not result in any statistical significance. The bar graph in
Figure 1B shows the average change in BMI from baseline at week 16 for each of the
five treatment groups. A one-way ANOVA did not demonstrate any significance.
The line graph in Figure 2A displays the average waist-to-hip ratio for each of the
five treatment groups for each visit after controlling for baseline. A one-way repeated
measures ANOVA demonstrated a significant difference (p < 0.05) between treatment
groups. The bar graph in Figure 2B shows the average change in BMI from baseline at
week 16 for each of the five treatment groups. A one-way ANOVA did not demonstrate
any significance, although the general trend for all treatment groups, and not the control
group, to decrease in waist-to-hip ratios from baseline to week 16. The Figure 2C
displays the average waist circumference measurement for each of the five treatment
groups after controlling for baseline. A one-way repeated measures ANOVA
demonstrated a significant difference (p < 0.05) between treatment groups. All groups,
except for the control group, tended toward a smaller waist circumference at the end of
the 16-week intervention.
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Figure 1.

A.

B.

Figure 1. (A) The average BMI for each of the five treatment groups calculated for all
five visits after controlling for baseline. No significance was found. (B) The average
change in BMI from baseline at week 16 for each of the five treatment groups. No
significance was found. Body mass index, BMI; Omega-3 fatty acids, O3FA.
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Figure 2.

A.

B.

C.

Figure 2. (A) The average waist-to-hip ratio for each of the five treatment groups
calculated for all five visits after controlling for baseline. Significance was found
between treatment groups (p < 0.05). (B) The average change in waist-to-hip ratio from
baseline at week 16 for each of the five treatment groups. No significance was found. (C)
The average waist circumference measurement for each of the five treatment groups
calculated for all five visits after controlling for baseline. Significance was found
between treatment groups (p < 0.05). Omega-3 fatty acids, O3FA.
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Sleep Quality
Sleep quality was assessed by utilizing both The Pittsburgh Sleep Quality Index
questionnaire (PSQI), as well as wrist actigraphy, during the course of the study.
Sleep: The Pittsburgh Sleep Quality Index (PSQI)
The PSQI Global Scores taken at the beginning of each participants’ visit were
calculated and recorded with the scores of the other participants in their respective
treatment groups. The average PSQI Global Scores for each of the five treatment groups
was calculated for each visit. The line graph in Figure 3A shows the average PSQI
Global Score for each of the five treatments groups for each visit after controlling for
baseline A one-way repeated measures ANOVA demonstrated a strong significant effect
(p < 0.0001) over time. The bar graph in Figure 3B shows the average change in PSQI
score from baseline to week 16 for each of the five treatment groups. A one-way
ANOVA demonstrated significant differences (p < 0.01) between treatments groups,
specifically the O3FA and the Protein + O3FA groups.
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Figure 3.

A.

B.

Figure 3. (A) The Global PSQI Score average for each of the five treatment groups
calculated for all five visits after controlling for baseline. Significance was found for time
(p < 0.0001). (B) The average change in Global PSQI score from baseline at week 16 for
each of the five treatment groups. Significance was found for treatment, between the
O3FA and the Protein + O3FA groups (p < 0.01). Omega-3 fatty acids, O3FA; Pittsburgh
sleep quality index, PSQI.
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Sleep: Wrist Actigraphy
The ActiGraph monitors were collected from each participant at the beginning of
the baseline, week 8, and week 16 visits along with the corresponding sleep diary. Wrist
actigraphy data was downloaded and analyzed using ActiLife v6.13.4 software
(Pensacola, FL). Sleep times were verified and corrected by comparing the sleep diaries
against the raw data downloaded. The sleep data was then analyzed to find total sleep
time, total minutes in bed, sleep efficiency, number of awakenings, and length of
awakenings.
The line graph in Figure 4A displays the average Sleep Efficiency (total sleep
time divided by time in bed) as a percentage, for each treatment group after controlling
for baseline sleep efficiency. A one-way repeated measures ANOVA did not demonstrate
significance. The line graph in Figure 4B displays the average Total Sleep Time in
minutes for each treatment group after controlling for baseline. A one-way repeated
measures ANOVA did not demonstrate significance. The line graph in Figure 4C
displays the average Total Time in Bed in minutes for each treatment group after
controlling for baseline. A one-way repeated measures ANOVA did not demonstrate
significance. Figure 5A shows a line graph depicting the average Number of
Awakenings for each group after controlling for baseline. A one-way ANOVA
demonstrated significance for time (p < 0.05), as well as between treatments (p < 0.05).
Figure 5B shows a line graph depicting the average Wake after Sleep Onset in minutes
for each group after controlling for baseline. A one-way ANOVA demonstrated
significance for time (p < 0.05), as well as between treatments (p < 0.05).
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Figure 4.

A.

B.

C.

Figure 4. (A) The average Sleep Efficiency for each of the five treatment groups
calculated for all five visits after controlling for baseline. No significance was found. (B)
The average Total Sleep Time for each of the five treatment groups calculated for all five
visits after controlling for baseline. No significance was found. (C) The average Time in
bed for each of the five treatment groups calculated for all five visits after controlling for
baseline. No significance was found. Omega-3 fatty acids, O3FA.
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Figure 5.

A.

B.

Figure 5. (A) The average Number of Awakenings for each of the five treatment groups
calculated for all five visits after controlling for baseline. Significance was found for both
time (p < 0.05), as well as between treatment groups (p < 0.05). (B) The average Number
of Awakenings for each of the five treatment groups calculated for all five visits after
controlling for baseline. Significance was found for both time (p < 0.05), as well as
between treatment groups (p < 0.05). Omega-3 fatty acids, O3FA.
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Mood: Profile of Mood States Questionnaire (POMS)
The POMS questionnaires filled out at the beginning of each participants’ visit
were recorded and compiled to produce a score for each of the following: Total Mood
Disturbance (TMD), Anger, Confusion, Depression, Fatigue, Tension and Vigor. These
scores were recorded with those of the other participants in their respective treatment
groups. The average POMS score for each of the five treatment groups was calculated per
mood distinction category for each visit.
The line graph Figure 6A shows the average TMD score for each of the five
treatments groups for each visit after controlling for baseline. A one-way repeated
measures ANOVA did not demonstrate significance. The bar graph in Figure 6B shows
the average change in TMD score from baseline at week 16 for each of the five treatment
groups. A one-way ANOVA demonstrated no significance.
Figure 7A displays the average Anger score for each of the five treatments
groups for each visit after controlling for baseline. A one-way repeated measures
ANOVA did not demonstrate significance. Figure 7B displays the average Confusion
score for each of the five treatments groups for each visit after controlling for baseline. A
one-way repeated measures ANOVA demonstrated significance (p < 0.05) between
treatment groups. Figure 7C displays the average Depression score for each of the five
treatments groups for each visit after controlling for baseline. A one-way repeated
measures ANOVA did not demonstrate significance. Figure 7D displays the average
Fatigue score for each of the five treatments groups for each visit after controlling for
baseline. A one-way repeated measures ANOVA did not demonstrate significance
Figure 7E displays the average Tension score for each of the five treatments groups for
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each visit after controlling for baseline. A one-way repeated measures ANOVA
demonstrated significance (p < 0.05) between groups. Figure 7F displays the average
Vigor score for each of the five treatments groups for each visit after controlling for
baseline. A one-way repeated measures ANOVA demonstrated significance (p < 0.05)
between treatment groups.
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Figure 6.

A.

B.

Figure 6. (A) The average TMD score for each of the five treatments groups for each
visit after controlling for baseline. No significance was found. (B) The average change in
TMD score from baseline at week 16 for each of the five treatment groups. No
significance was found. Omega-3 fatty acids, O3FA.

23

Figure 7.

A.

B.

C.

D.

E.

F.

Figure 7. (A) The average Anger score for each of the five treatments groups for each
visit after controlling for baseline. No significance was found. (B) The average Confusion
score for each of the five treatments groups for each visit after controlling for baseline.
Significance was found between treatment groups (p < 0.05). (C) The average Depression
score for each of the five treatment groups after controlling for baseline. No significance
was found. (D) The average Fatigue score for each of the five treatments groups for each
visit after controlling for baseline. No significance was found. (E) The average Tension
score for each of the five treatments groups for each visit after controlling for baseline.
Significance was found between treatment groups (p < 0.05). (F) The average Vigor
score for each of the five treatments groups for each visit after controlling for baseline.
Significance was found between treatment groups (p < 0.05). Omega-3 fatty acids,
O3FA.
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Discussion
The rapid growth of the older population of the United States’ and this
population’s increasing health risks including obesity, chronic diseases, decreased quality
of life, and premature death are expected to slow down anytime soon [1]. Determining
the health risks associated with particular obesity levels has been shown to best be
measured through BMI with waist measurements distinguishing health risks for a given
BMI group [4]. The risk of obesity as well as poor sleep increases with age [22]. Poor
sleep in turn, may lead to more emphasized signs of aging, obesity, and other hardships.
Nutrition continues to be a key factor in preventing both muscle loss and body fat gain.
Nutrition further emerges, as a preventative strategy to decrease sleep and mood
dysregulation that comes with aging. Studies have shown that healthy aging is correlated
with high O3FA consumption [10], as well as high protein diets via decreased body fat
[11]. Guidelines for the promotion of healthy aging are needed.
Through this particular study, sleep, mood, BMI, waist circumference, and waistto-hip ratio measurements were all utilized in an attempt to determine the synergistic
effect of protein and omega-3 fatty acid supplementation in a particular sector of the
aging population—postmenopausal women. While the intervention lasted 16 weeks,
improvements in any of the above measures were recognized as potential clues to nutrient
supplementation’s effect on healthy aging.
Current literature suggests that poor sleep quality, as assessed by a variety of
measures, is linked to low protein intake [7]. The findings of this study are aligned with
this idea, as a major trend for the Protein + O3FA group to decrease in PSQI Global
Score more than any other group from baseline to week 16. The significantly lowered
25

Global PSQI score from baseline to week 16 for the Protein + O3FA group as compared
to the just O3FA group also aligns with the literature stating that increased intake of
dietary protein has shown the ability to improve sleep quality as measured by Global
PSQI scores [23]. High-protein diets have been found to improve sleep quality through
decreasing the occurrence of wake episodes during sleep [7]. ActiGraph measurements
for sleep quality did not align with the current literature for improved sleep with
increased intake of dietary protein. The supplementation of protein did not show
consistently clear improvement for these measures of sleep quality, but this could have
due to small group sizes and the short duration of the intervention.
Postmenopausal women’s sleep disturbances have been linked to mood symptoms
in current literature, particularly depression and anxiety [16]. Current literature has
presented the possibility of O3FAs to decrease depression [9]. POMS Depression scores
trends aligned with the literature. The O3FA and Protein + O3FA groups both
demonstrated the greatest trends in a decreased depression score from baseline to week
16, showing an improved mood state with respect to the measurement of depression. In
fact, the Protein + O3FA group both tended to trend toward a lower, improved mood
score from baseline to week 16 for: TMD, Anger, Depression, Fatigue, and Tension.
While BMI values did not display much improvement, both waist circumference
and waist-to-hip ratios displayed a trend for all treatment groups, and not the control
group, to demonstrate a decline from baseline to week 16. This is supported by the
literature, as O3FA and protein consumption are known, individually, to decrease body
fat [10, 11]. Postmenopausal women are afflicted by a great gain in waist circumference
and waist-to-hip ratio when compared to their premenopausal counterparts [14]. Current
26

literature has found that dietary supplementation may aid to combat the fat gains
experienced by postmenopausal women [10, 11]. The statistical significance found
between treatment groups for waist-to-hip ratios, waist circumference, and the general
trend shown in for all groups with dietary supplementation of whey protein and/or
O3FAs to decline in waist-to-hip ratios and waist circumference measurements, aligns
with the current literature.
The effect of additional protein, O3FAs, and the combination of both protein and
O3FA supplementation showed potential to counter the risks often associated with aging
adult by promoting health aging. Protein and O3FAs appeared to positively impact the
nutrition of aging adults and thus affect aging through improving various aspects of
subjective sleep, mood, and anthropometric measurements.
Limitations of this study included a small sample size, anthropometric human
error, sleep diary human error, and subject compliance. Recruitment for human studies,
combined with inclusion and exclusion criteria, is never an easy task. As the intervention
was over the course of 16-weeks and included morning study day visits, total of 34
participants fully completed the study. This sample size is not larger enough to be fully
representative of the given population—aging United States’ postmenopausal women.
Despite standardizing points to measuring waist circumferences, hip widths, and utilizing
the same stadiometer and balance scales for all visits and participants, anthropometric
human error during the course of the intervention could have occurred. The sleep diaries
given to participants included instructions, but human error in recording proper times
could have altered ActiGraph results when verifying the ActiGraph monitors with
potentially incorrect sleep diaries. Finally, as the consumption of supplements—whether
27

whey protein, O3FA, or soybean oil placebo—was left to the participant on their own
time in between visits, subject compliance cannot be fully verified. Subjects checked
boxes as reminders for supplement consumption, returned empty supplement packaging,
and were verbally asked their compliance from visit-to-visit, but this does not ensure
correct compliance if perhaps a supplement dosage was mistakenly missed.
Further study on the exact processes affected by protein and O3FAs in the aging
adults’ body both individually and combined are needed. The epidemics of obesity,
chronic diseases, and overall decreased quality of life currently impact many aging
adults. This supports deeper inquiry into the bodily impact of nutrient supplementation.
Postmenopausal women, in particular, tend to experience significant fat gain, highly
report sleep disturbance, and are prone to mood disturbances at a higher rate compared to
their male counterparts [15, 16, 17]. This study considered a demographic with much
need for healthy aging guidelines that is overall underrepresented in research. Protein and
O3FAs appear to have the potential to assist in achieving healthier aging, and more
research is called for to assist both the afflicted aging, and specifically postmenopausal,
demographic.
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